

Loughborough University Institutional Repository

Human, animal and environmental contributors to antibiotic resistance in low resource settings: integrating behavioural, epidemiological and One Health approaches

This item was submitted to Loughborough University's Institutional Repository by the/an author.

Citation: ROUSHAM, E.K., UNICOMB, L. and ISLAM, M.A., 2018. Human, animal and environmental contributors to antibiotic resistance in low resource settings: integrating behavioural, epidemiological and One Health approaches. *Proceedings of the Royal Society B: Biological Sciences*, 285: 20180332.

Additional Information:

- This paper was accepted for publication in the journal *Proceedings of the Royal Society B: Biological Sciences* and the definitive published version is available at <http://doi.org/10.1098/rspb.2018.0332>

Metadata Record: <https://dspace.lboro.ac.uk/2134/32555>

Version: Accepted for publication

Publisher: © The Authors. Published by The Royal Society.

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Please cite the published version.

Human, animal and environmental contributors to antibiotic resistance in low resource settings: behavioural, epidemiological and One Health approaches

Journal:	<i>Proceedings B</i>
Manuscript ID	RSPB-2018-0332.R1
Article Type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Rousham, Emily; Loughborough University, School of Sport, Exercise and Health Sciences Unicomb, Leanne; International Center for Diarrheal Disease Research, Bangladesh Islam, Mohammad; International Center for Diarrheal Disease Research, Bangladesh
Subject:	Health and Disease and Epidemiology < BIOLOGY, Microbiology < BIOLOGY, Environmental Science < BIOLOGY
Keywords:	low and middle income countries, one-health, antibiotics
Proceedings B category:	Ecology

1 **Human, animal and environmental contributors to antibiotic resistance in low**
2 **resource settings: integrating behavioural, epidemiological and One Health**
3 **approaches**

4

5 Dr Emily K Rousham¹, Dr Leanne Unicomb², Dr Mohammad Aminul Islam³

6 ¹ Centre for Global Health and Human Development, School of Sport, Exercise and
7 Health Sciences, Loughborough University, Loughborough, LE11 3TU, UK.

8

9 ² Environmental Intervention Unit, Infectious Disease Division, International Centre
10 for Diarrheal Disease Research, Dhaka, Bangladesh.

11

12 ³ Laboratory Sciences and Services Division, International Centre for Diarrheal
13 Diseases Research, Dhaka, Bangladesh.

14

15 Corresponding author: Emily Rousham

16 email: e.k.rousham@lboro.ac.uk

17

18

19

20

21 .

22

23 **Abstract**

24 Antibiotic resistance (ABR) is recognised as a One Health challenge because of the
25 rapid emergence and dissemination of resistant bacteria and genes among humans,
26 animals and the environment on a global scale. However, there is a paucity of
27 research assessing ABR contemporaneously in humans, animals and the
28 environment in low resource settings. This critical review seeks to identify the extent
29 of One Health research on antibiotic resistance in low and middle income countries
30 (LMICs). Existing research has highlighted hotspots for environmental contamination;
31 food-animal production systems that are likely to harbour reservoirs or promote
32 transmission of ABR as well as high and increasing human rates of colonisation with
33 ABR commensal bacteria such as *Escherichia coli*. However, very few studies have
34 integrated all three components of the One Health spectrum to understand the
35 dynamics of transmission of AMR and the prevalence of community-acquired
36 resistance in humans and animals. Microbiological, epidemiological and social
37 science research is needed at community and population levels across the One
38 Health spectrum in order to fill the large gaps in knowledge of ABR in low resource
39 settings.

40

41 **Introduction**

42 The One Health approach aims to attain optimal health for people, animals and the
43 environment (1). Antibiotic resistance (ABR) is recognised as a One Health
44 challenge because of the rapid emergence and dissemination of resistant bacteria
45 and genes among humans, animals and the environment at a global scale (2).
46 Global and National Action Plans (NAPs) to tackle antimicrobial resistance (AMR)
47 have been instigated and coordinated through the tripartite alliance of the World
48 Health Organization (WHO), the Food and Agricultural Organization (FAO) and the
49 World Organization for Animal Health (OIE). All countries are now tasked with
50 implementing NAPs on AMR through multisectoral working to ensure comprehensive
51 surveillance, monitoring and policy implementation across human, animal and
52 environmental domains (3). However, research on ABR adopting a truly One Health
53 approach is relatively sparse in low and middle income countries. A recent WHO
54 review concluded that high quality data relating to prevalence and abundance of
55 resistant bacteria and genes in humans, animals and food are missing, especially for
56 community-acquired infections in low-income countries (4). These gaps in evidence

57 will limit the ability to assess progress towards meeting the goals of NAPs in many
58 countries.

59

60 This critical review examines the extent of One Health research on ABR in low and
61 middle income settings. Specifically, the review seeks to identify research that
62 directly assesses ABR across one or more domain of the human, animal, and
63 environmental system. A further aim is to evaluate evidence of shared resistance
64 profiles in human and animal hosts acquired by direct or indirect (via the
65 environment) transmission pathways.

66

67 **The human health risk of ABR in LMICs**

68 Clinical human studies on hospitalised patients constitute the majority of current
69 knowledge of ABR in LMICs. A number of syntheses have highlighted the most
70 common resistant organisms, susceptibility profiles and resistant mechanisms in
71 clinical settings by LMIC region or countries (5–8). A recent review found 90% of
72 studies of neonatal bacterial resistance in LMICs are hospital-based with insufficient
73 data from community settings to draw conclusions (9). Whilst valuable for monitoring
74 and promoting stewardship in healthcare settings, these studies shed little light on
75 the determinants and risk factors for ABR in the wider population.

76

77 The health threat of ABR is of particular concern in LMICs because of the greater
78 likelihood of community-acquired resistant infections, the high infectious disease
79 load in the general population, poor coverage of safe water and sanitation; poor
80 access to health services and weak regulation and enforcement of antibiotic use in
81 food production and healthcare (10–12). Further health risks stem from some of the
82 transmissible ABR mechanisms that have emerged from low resource settings with
83 subsequent global dissemination. Examples include extended spectrum beta
84 lactamases (ESBLs) conferring resistance to third generation cephalosporins (3CG);
85 carbapenem resistance conferred by enzymes such as New Delhi metallo-beta-
86 lactamases (NDM-1)(13), and colistin resistance via the gene *mcr-1* (14). These
87 resistance mechanisms are carried on mobile genetic elements hosted by different
88 bacterial species in humans, animals, food, and the environment providing multiple
89 routes of transmission.

90

91 **Bacteria of relevance to One Health approaches in LMICs**

92 The highest priority bacteria for ABR prevention, categorised as critical by the WHO,
93 include *Acinetobacter baumannii*; *Pseudomonas aeruginosa* and *Enterobacteriaceae*
94 (4). Of the *Enterobacteriaceae*, *E. coli* has the greatest likelihood for animal-human
95 transmission and is a major organism of community associated ABR, carrying
96 resistance to carbapenems and third generation cephalosporins. Pathogenic strains
97 of *E. coli* are the leading cause of human urinary tract infection, bacteraemia and
98 gastroenteritis. As a commensal bacterium, *E. coli* colonises the gut of humans and
99 animals, as well as being ubiquitous in soil, plants, vegetables and water (15). For
100 these reasons, *E. coli* is commonly chosen as a sentinel organism for One Health
101 studies of ABR (16). Other bacteria relevant to food-borne disease transmission are
102 *Salmonella* spp. and *Campylobacter* spp. with potential for resistance to third
103 generation cephalosporins and fluoroquinolone. These are ranked by the WHO as
104 high priority rather than critical (4).

105

106 **Scope of review**

107 The databases Medline, Scopus, Science Direct and Clinical Trials were searched
108 using the MeSH term 'drug resistant bacteria' with alternative terms 'antibiotic',
109 'antimicrobial resistance' or 'AMR'; and 'LMIC' or alternative terms (developing
110 countries/global health/developing nations/low income countries/middle income
111 countries). Searches were filtered for journal articles or reviews published in English
112 language from 2007 to 2017. Studies conducted on inpatients samples were
113 excluded, as were studies reporting therapeutic regimes, vaccines or diagnostics.
114 Studies focussing on resistant bacteria of relevance to the One Health paradigm
115 were identified. Hand searches were carried out for referenced citations and new
116 articles. Of all retrieved studies, those that directly assessed antibiotic resistant
117 bacteria or genes in community-based studies of humans, food-producing animals or
118 the environment were included for general review. Of these, the final table of papers
119 (Supplementary Table 1) included those that examined antibiotic resistance in one or
120 more domain of the environment, humans and food-producing animals.

121

122 **The human reservoir of ABR in LMICs**

123 The dissemination of *Enterobacteriaceae* (bacteria colonising human guts, with or
124 without disease) carrying extended spectrum beta-lactamase (ESBL) genes is

125 increasing in humans and animals globally (17). From 2000-2008, reported
126 colonisation rates with ESBL-producing *E. coli* (ESBL-EC) were generally less than
127 10%. After 2008, however, rates increased rapidly to as high as 60% in some LMICs
128 (18) with India and China harbouring some of the largest reservoirs of ESBL genes
129 (19). A recent systematic review and meta-analysis estimated the prevalence of gut
130 colonisation with ESBL-EC in healthy humans at 14% globally (20) with rates of 22%
131 in Southeast Asia and Africa (20).

132

133 **Risk factors for human colonisation with resistant bacteria**

134 The increase in colonisation with resistant ESBL-EC has been dramatic, but factors
135 associated with the acquisition of resistant bacteria in humans are not well
136 established. Some of the highest reported rates of colonisation are from China,
137 where 62.8% of *E. coli* isolates were ESBL-producing from outpatients in town
138 hospitals across three regions of Shandong province (21). These rates were
139 considered to reflect contact with food-producing animals in rural areas (21). In other
140 areas of rural China, rates of infection with ESBL-EC from hospitals ranged from 57%
141 in North China to 30.2% in East China (22). For some resistance genes, extremely
142 high prevalence rates have been reported. In India, 91% of faecal samples from
143 human communities carried quinolone-resistance genes, compared to 24% in human
144 samples from Sweden (23). Most of these studies are characterised by cross-
145 sectional designs with unspecified sampling strategies, hence representativeness is
146 hard to assess.

147

148 Studies of children in LMICs, whilst few, have shown 5.6% colonisation with ESBL-
149 producing enteric bacteria among under 5 year olds in Nicaragua (24) and 3% in
150 children under 5 years in Madagascar (25). Multi-drug resistant *E. coli* were isolated
151 from 55% of healthy middle-class children aged 10-24 months (n=15) in Bangladesh,
152 some of which were ESBL-producing (26).

153

154 Occupational risk of resistance carriage has rarely been assessed. Korean fishery
155 workers, who were exposed to antibiotics used in aquaculture, had a significantly
156 higher proportion of *E. coli* isolates with resistance to cephalothin, tetracycline, and
157 trimethoprim-sulfamethoxazole compared with a 'control' group of restaurant workers.
158 Rates of colonisation with multidrug resistant *E. coli*, however, were similar (27).

159 There was no assessment of antibiotic exposure or consumption and no control for
160 potentially confounding effects.

161

162 Socio-demographic risk factors for ABR colonisation or infection are likely but poorly
163 researched. In Madagascar, higher socio-economic status, assessed by occupation,
164 was associated with lower colonisation rates with ESBL-producing
165 Enterobacteriaceae in a community based survey of adults (28). Managers and
166 employers had a significantly lower risk of ESBL-EC carriage than manual and non-
167 manual occupation groups (4% versus 26.5% and 30% respectively) (28). These
168 differences may be mediated by housing quality, differential occupational exposures
169 or access to water, sanitation and hygiene facilities.

170

171 The transmission of human colonisation with resistant organisms from LMICs to
172 other regions is illustrated by studies of travellers. International travellers were four
173 times more likely to be colonised by ESBL-EC than non-travellers in a systematic
174 review (20). Similarly, a prospective study of Dutch back-packers reported that 34%
175 of travellers carried ESBL-EC after their return, with highest acquisition rates among
176 those who had travelled to southern Asia (29). The median duration of colonisation
177 was 30 days, suggesting that colonisation is transient, but onward transmission to
178 household members was detected, demonstrating human-human transmission (29).
179 The human carriers with more resistant forms (e.g. carbapenem resistance) also had
180 greater persistence (29).

181

182 **The role of food-producing animals in One Health approaches to AMR** 183 **transmission in LMICs**

184 Food-producing animals, fish and seafood in LMICs provide large reservoirs for
185 antibiotic resistance because of the high use of antibiotics for prophylaxis, growth
186 promotion and metaphylaxis. The BRIC economies are estimated to have the
187 highest consumption of antimicrobials for livestock in LMICs; projected to increase
188 by 99% in Brazil, Russia, India, China and South Africa from 2010 to 2030 (30). The
189 intensification of farming in LMICs corresponds with the increasing consumption of
190 animal protein, particularly meat, fish, poultry and eggs (31). Urbanisation,
191 population growth and rising incomes contribute further to this demand for animal-
192 based foods (32).

193

194 Poultry production is considered a high risk for ABR emergence in low income
195 settings, particularly in smaller-scale unregulated operations. Commercial poultry
196 farming is highly profitable and ideally suited to settings where land is scarce (33).
197 Poultry commonly receive higher quantities of antibiotics than other animal livestock
198 (34)(35), and resistance is more likely to develop in conditions of animal
199 overcrowding and poor sanitation.

200

201 In Vietnam, a high prevalence of MDR *E. coli* (81.3%), but low prevalence of ESBL-
202 EC (3.2%) was reported in a survey of 208 household and small-scale chicken farms
203 in the Mekong Delta (36). Antibiotic use was significantly associated with MDR
204 resistance in poultry samples, with antimicrobials being a common addition to
205 commercial feeds in Vietnam. The presence of an integrated fish pond on farms was
206 associated with ESBL-EC in poultry; attributed to the chickens acquiring resistance
207 from water contaminated with human sewage (36).

208

209 The type of poultry farming (broiler versus layer) and the size and scale of farming
210 (contracted vs independent) is associated with rates of ABR colonisation. Broiler
211 production relies on rapid growth of chicks to increase profit. To this end, antibiotics
212 are applied as additives to feed or water to promote growth. Among 16 poultry farms
213 (broiler and layer) in India, 100% reported using antimicrobials for routine
214 prophylaxis, and 67% reported using antibiotics as growth promoters (37). The
215 prevalence of resistance to multiple antimicrobials was higher in farms (both broiler
216 and layer) that used antimicrobials for growth promotion, suggesting an association
217 between usage and resistance (37). In urban Ghana (Kumasi and Accra) 56% of
218 poultry farmers reported routine antibiotic use from 75 poultry farms with a range of
219 flock size (38). In a survey of 20 poultry farmers in Ecuador, 80% reported using
220 antibiotic supplements but no differences were observed in ABR among birds with
221 and without supplementation (39).

222

223 In India, broiler poultry were more likely than layers to carry ESBL-EC (87% versus
224 42% respectively) (37) correspondingly with higher reported antibiotic use in broiler
225 farms. In Ecuador, significantly higher rates of resistant *E. coli* were reported among
226 commercially produced birds (layers and broilers) compared to 'backyard'

227 (household) poultry. Resistance to tetracycline was detected in 78% of production
228 birds compared with 34% of household birds; resistance to sulfisoxazole, and
229 trimethoprim-sulfamethoxazole were 69% and 63% respectively in production birds
230 compared with 20% and 17% in household birds ($p < 0.001$)(39). High and
231 uncontrolled usage of antimicrobials (most commonly sulfonamides, tetracyclines
232 and fluoroquinolones) was noted in 98 small-scale chicken farms in Yaoundé,
233 Cameroon. Almost half of farms did not observe a withdrawal period before the
234 poultry went to market (40).

235

236 Qualitative research among poultry workers and those involved in the food chain can
237 shed important light on the potential drivers of antibiotic use (41). In-depth interviews
238 with commercial food animal farms, retailers and veterinarians in Cambodia
239 identified four main drivers: the belief that antibiotics were necessary for animal
240 raising; limited knowledge; unrestricted antibiotic access and weak monitoring and
241 control systems (41). There were also reports of switching from an animal-use
242 antibiotic to a human-use antibiotic if treatment was perceived to be ineffective (41).

243

244 In domestic settings and subsistence farming there is less evidence of inappropriate
245 antibiotic use in livestock. Antibiotics are used primarily for treatment rather than as
246 growth promoters or prophylaxis and evidence suggests the prevalence of antibiotic
247 resistance in these farming systems is low. Free-range pigs in Tibet raised without
248 antibiotic administration had low levels of antibiotic resistant *E. coli* relative to more
249 intensive farm systems (42). Backyard poultry in India were found to have no cases
250 of ESBL-EC in 360 sampled birds (43). In a contemporaneous comparison of poultry,
251 the prevalence of ESBL-EC in poultry meat was 46% from broiler production
252 compared with 15% in free-range production (44). In a rural survey of households
253 owning cattle or poultry in Bangladesh 53.4% (of 521) reported using at least one
254 animal treatment in the previous six months. However, 'medicine' (likely including
255 antibiotics) and feed additives were generally only used in cases of diarrhoea or
256 fever in livestock (45).

257

258 Antibiotic use in aquaculture is important as a potential driver of ABR in aquatic
259 systems in LMICs (46). Of 94 fish and shrimp freshwater farms surveyed in Vietnam,
260 72.3% used at least one antibiotic (47). Higher antibiotic use was associated with

261 farms that had a higher density of fish or shrimp and higher total annual production.
262 The same study assessed fish products in local markets, but with no direct supply
263 connection to farms. Of retail shrimp and fish samples from local markets, 26.9%
264 (28/104) were positive for fluoroquinolone and tetracycline antibiotic residues,
265 indicating a lack of adequate withdrawal times on farms. Quinolone and ESBL
266 resistance genes have been identified in retail fish farmed across Guangdong
267 province in southern China (48). Resistance rates were particularly high to the
268 antimicrobial agents commonly used in fish cultivation: tetracyclines, florfenicol and
269 co-trimoxazole, strongly indicating links between antimicrobial use in fish farming
270 and resistance (48).

271

272 **Evidence of animal to human transmission of ABR**

273 Studies linking animal and human profiles of resistance have been based
274 predominantly on indirect associations. In China, the ESBL-producing enzyme CTX-
275 M-55 is increasing both in colonised healthy humans and community-acquired *E. coli*
276 infections (22). Prior to this, the enzyme was a leading form of resistance in food-
277 producing animals (globally since 2002, and in China since 2005) (49,50) suggesting
278 possible transmission from animals to humans (49). Whole genome sequencing
279 (WGS) of resistant bacterial isolates allows more direct associations to be made
280 between animal and human isolates. WGS analysis from broiler poultry in India
281 confirmed two globally emergent human pathogenic lineages of *E. coli* identified
282 among the poultry *E. coli* isolates (44), indicating that commercial poultry meat is a
283 potential carrier of human *E. coli* pathotypes (44).

284

285 Abdissa et al. (51) examined the prevalence of O157:H7 in beef cattle at slaughter;
286 beef carcasses at retail shops, and humans with diarrhoea attending health centres
287 in Ethiopia. *E. coli* O157:H7 was found at a low prevalence in slaughtered cattle (2%)
288 but there were no positive samples for *E. coli* O157:H7 from human diarrhoea cases.
289 The findings were limited by small sample size (n=70) and no direct or putative
290 pathways of transmission (51).

291

292 Movement of food and animals has also led to the global dissemination of antibiotic
293 resistance. The plasmid-mediated resistance mechanism to the antibiotic colistin,
294 *mcr-1*, was first identified in China among intensively farmed pigs (52). Since this

295 discovery in 2015, *mcr-1* has been detected in Enterobacteriaceae strains from five
296 continents: in humans; food; farm and wild animals, and aquatic environments (53).

297

298 **ABR dissemination from food-producing animals to the environment**

299 ABR dissemination from food-producing animals to the surrounding environment
300 takes place through either the excretion of antimicrobials in urine or faeces into
301 surface waters and soils, or the application of animal manure as fertilizer to soil or
302 ponds. Untreated animal waste is used for a variety of purposes in subsistence
303 economies. Poultry waste is commonly used for feeding of fish and shellfish in
304 aquaculture (54). Intestines from poultry are also used as feed for aquaculture,
305 leading to higher levels of resistance in *Enterococcus* spp. isolates in fish intestines
306 (55).

307

308 In China, duck faecal and surface water samples were analysed from a large
309 breeding farm where one-day old ducklings were routinely injected with cefiofur (50).
310 The prevalence of cefiofur-resistant *E. coli* isolates and ESBL gene types in pond
311 water samples were similar to those of duck faecal samples. Faecal contamination
312 therefore had a measurable effect on the environmental prevalence of ABR bacteria
313 and genes (50).

314

315 Other studies in China observed that soil treated with pig manure was positive for
316 ESBL-EC, with *bla*_{CTX-M} being the predominant ESBL gene whereas no resistant
317 isolates were detected in control soil samples (56). Three isolates from soil had
318 above 90% genetic similarity with strains from pig farm samples, pointing strongly to
319 transmission of AMR organisms from pig manure to the environment (56).

320

321 **Animal studies including assessment of farm workers**

322 Very few studies have examined the resistance profiles of bacteria and genes in
323 food-producing animals and directly-exposed humans in LMICs (supplementary
324 Table 1). Donkor et al. (57) assessed MDR *E. coli* in cattle and their farmers in
325 Ghana. Animal and human *E. coli* isolates showed high levels of MDR antibiotic
326 resistance (70.6% and 97.7%, respectively), although animal-derived isolates had
327 high resistance to five antimicrobials (cefuroxime, cotrimoxazole, tetracycline,
328 ampicillin and amikacin) and human-derived isolates had higher resistance to

329 chloramphenicol and gentamycin. Thus, while resistance was high in both animals
330 and humans, the susceptibility profiles were different.

331

332 A study of ABR in faeces and milk from healthy dairy cows and their associated dairy
333 farmers from 23 farms in Ethiopia showed 10% of samples from cows and 13% of
334 the human faecal samples were positive for *Salmonella* spp. 58% (14/24) of all
335 *Salmonella* spp. isolates were resistant to three or more antibiotics (58). There were
336 no data on non-dairy workers, however, to assess whether dairy farmers had higher
337 prevalence through direct exposure to cows. Such studies ideally require molecular
338 methods to examine the phylogenetic associations between human and animal
339 isolates which may then provide evidence of common lineages (59).

340

341 **Anthropogenic influences on the environmental resistome in LMICs**

342 Environmental contamination with antibiotic residues and resistant genes due to
343 human activity has been demonstrated from pharmaceutical plants, hospital effluents
344 and untreated wastewater (7) and may be a leading driver of ABR in low resource
345 settings (60). In central India, hospital effluent contained *E. coli* resistant to
346 extended-spectrum cephalosporin and fluoroquinolone antibiotics (61,62). In
347 Hyderabad, 95% of water samples taken near drug manufacturing facilities were
348 positive for ESBL and carbapenemase-producing Enterobacteriaceae (63). The latter
349 study found fluconazol concentrations 20 times in excess of the recommended
350 therapeutic dose (63). In Bangladesh, 71% of wastewater samples next to hospitals
351 (51/72) were positive for NDM-1-producing bacteria compared to 12% of wastewater
352 samples in community areas in the same city of Dhaka (64). In Nicaragua, ESBL-EC
353 were detected in hospital sewage samples with all isolates encoding for the *bla*_{CTX-M}
354 gene (65). Higher concentrations of antibiotic resistance genes were detected
355 downstream from pharmaceutical industries in western Havana (66).

356

357 Human and animal exposures to ABR in the environment occur through drinking
358 water supplies that have not been disinfected. In Dhaka city, 36% of 223 *E. coli*
359 isolates from water supply samples were multi-drug resistant (67). 26% of well-water
360 samples in Nicaragua were positive for ESBL-EC (65). Healthcare waste and solid
361 waste management are further pollutants and potential drivers of ABR in low income
362 settings (68–70). Refuse sites are attractive for human scavenging and recycling of

363 medical waste products, adding further exposure risk (69). These wastes often
364 contain heavy metals and other pollutants that co-select for ABR causing further
365 release of resistant genes (54).

366

367 Anthropogenic influences on the resistome have been inferred from 'natural'
368 experiments as shown by the increased ARG contamination of rural river waters in
369 India during the seasonal pilgrimage of urban residents to a religious site on the river
370 (71). Links have been demonstrated between human antibiotic use and
371 environmental contamination. Diwan et al. (72) compared the quantities of the seven
372 most commonly prescribed antibiotics in a hospital in India with the antibiotic
373 concentrations and susceptibilities of *E. coli* in hospital-associated water. A
374 significant correlation was observed with ciprofloxacin being the most common
375 antibiotic prescribed and having the highest concentration in water (72). However,
376 the effect of these antibiotics on *E. coli* isolates in water was not clear. Rutgersson et
377 al. (23) assessed the prevalence of fluoroquinolone antibiotics and quinolone-
378 resistant genes (*qnr*) in river water, sediment, well water and irrigation farmland near
379 a pharmaceutical manufacturing plant in India as well as the faecal concentration of
380 *qnr* genes in healthy humans. Around 42% of well-water; 7% of soil samples and 100%
381 of Indian river sediment samples were positive for *qnr* genes. In sediment there was
382 an association between fluoroquinolone and *qnr* gene concentrations, but no
383 associations were present in well-water or soil. The study failed to demonstrate
384 direct linkage between environmental exposure to quinolone-resistance genes and
385 the presence of *qnr*-genes in humans, largely because the prevalence of the gene
386 was so high in humans (91%) and human to human transmission was highly
387 probable (23).

388

389 **One Health studies across all three domains of humans, animals and the** 390 **environment**

391 Few studies in low resource settings have examined the presence of resistant
392 bacteria and genes in all three domains of humans, animals and the environment
393 (see supplementary Table 1). Dhaka et al. (73) assessed ABR in diarrhoeagenic *E.*
394 *coli* (DEC) in animals with diarrhoea (n=106), food products (n=68), environmental
395 samples (n=59) and infants with diarrhoea (n=103) in India. Of the four DEC
396 pathogens, enteroaggregative *E. coli* (EAEC) was the most common with a

397 prevalence of 16.5% in infants, 17.9% in young animals, 16.2% in foods and 3.4%
398 from environmental sources. Around 86% of isolates were resistant to three or more
399 classes of antibiotics (73). However, the study sampled hospitalised infants, and
400 animal samples were collected from private farms and veterinary clinics. The only
401 statistically significant similarities in antibiotic resistance profiles of EAEC isolates
402 were for ciprofloxacin (human versus environmental, and animal versus
403 environmental). This was explained by the widespread use of fluoroquinolones for
404 diarrhoea treatment which then leads to both human and animal ciprofloxacin-
405 resistant EAEC isolates that contaminate the environment through faecal waste (73).
406

407 Goat carcasses, faeces, equipment and environmental samples were examined in a
408 large abattoir in a pastoralist region of Ethiopia (74). Antibiotic resistant *E. coli* O157
409 were isolated from caecal contents, carcass swabs and water. Although the
410 prevalence was low (2.5%; 3.2% and 7.1%), all isolates were resistant to two or
411 more antimicrobials. The study identified *E. coli* resistance to drugs that are not used
412 in goats and suggested that human infections may be the original source of
413 resistance that is transferred to livestock in this ecosystem.

414
415 A comprehensive One Health study of AMR was carried out in a rural community in
416 El Salvador and a peri-urban town in Lima, Peru, using high throughput and shot-gut
417 metagenomics (75). Samples were collected from humans, domesticated animals
418 and the environment (soil, water, sewage or latrines). Human-associated and
419 environmental resistomes were related along an ecological gradient corresponding
420 with input from human faeces (75). The study also identified key resistance genes
421 that cross habitat boundaries and determined their association with mobile genetic
422 elements. This is one of the most comprehensive studies across different ecological
423 zones that encompasses the human, animal and environmental resistome.

424

425 **Human-animal-environment interactions and socio-ecological behaviours**

426 Aside from assessing ABR prevalence, there is an increasing need to understand
427 behaviours, customs and practices that drive the evolution and transmission of
428 resistance in low-resource settings. In rural areas, households commonly share
429 living and sleeping areas with livestock (76) providing opportunities for transmission
430 of resistant bacteria and genes through faecal shedding or contact with animal

431 faeces. In rural Bangladesh, half of households reported that poultry slept in the
432 bedroom (45). Behaviours relating to the slaughter and processing of food-animals
433 is a route of human exposure to resistant enteric bacteria. Family members often
434 gather during the slaughter of poultry to say prayers. Handwashing with soap after
435 slaughtering poultry was reported for only 14% of observations in domestic settings
436 (33). After butchering, animal waste is often discarded on open land then scavenged
437 by dogs, wild birds and domestic poultry (33).

438

439 Biosecurity measures are often poor or absent in small-scale animal-food processing
440 facilities. In Ethiopia, observations within an abattoir reported the absence of soap,
441 running water and disinfectant during slaughter; the same buckets of water were
442 used for cleaning knives, washing hands, washing carcasses and washing the floor
443 (74). In Dhaka city, like many other urban areas in LMICS, poultry are slaughtered,
444 processed and sold on site without regulation of the preparation, selling or disposal
445 of solid waste (77). Liquid waste from markets, including blood, faeces and
446 wastewater is disposed into municipal drains through direct wash out (77). Other
447 potential sources of ABR transmission are shared surface waters used by humans
448 for bathing; fishing or washing of clothes and household items. Animals use the
449 same water for bathing and drinking while also grazing and defecating nearby (78).

450

451 Other behavioural risks may stem from food preparation and consumption. Raw or
452 undercooked meat is one of the most common means of transmission of *E. coli*
453 O157 to humans, but some communities, such as pastoralist groups in Ethiopia,
454 have strong preferences for raw meat consumption (74).

455

456 Information about antibiotic use in agriculture is increasing, but there are likely to be
457 many more undocumented practices around antibiotic use. Anthropological studies
458 among Somali pastoralist tribes in Ethiopia observed that antibiotics are occasionally
459 added to fresh unpasteurised milk before selling in unsterilized plastic containers
460 (79). This reflects the opportunistic use of inexpensive and readily available
461 antimicrobials as well as an adaptation to modern food processing and storage in
462 order to prolong the shelf life of milk produce.

463

464 **One Health surveillance programmes**

465 Large scale programmes for surveillance of food-producing animals and non-
466 hospitalised humans will provide much-needed data on the scale of ABR outside
467 healthcare settings. While the global antimicrobial surveillance system initiative
468 (GLASS) is focussing on human clinical surveillance, the WHO Alliance for Global
469 Integrated Surveillance on Antimicrobial Resistance is supporting and promoting
470 One Health programmes (16). A framework for national/regional surveillance has
471 been proposed to improve consistency and coverage of ABR reporting in LMICs (80).
472 Systems for monitoring and surveillance are also a high priority in NAPs among
473 countries with the required infrastructure.

474

475 Integrated food surveillance systems are being developed for food production
476 systems and food safety (16). Colombia has successfully piloted an integrated
477 surveillance system to monitor trends in antibiotic resistance on poultry farms,
478 abattoirs and retail markets (81). In Mexico, surveillance of foodborne pathogens
479 including *Salmonella* spp. and *Campylobacter* spp. is linked with human surveillance
480 data for the same pathogens (82).

481

482 Other national surveys are underway to contribute to understanding the drivers of
483 AMR. INDEPTH is a network currently comprising 37 Health Demographic
484 Surveillance System Sites in 20 LMICs (80). This network aims to determine the true
485 prevalence of antibiotic resistance; to relate hospital-reported prevalence of ABR
486 with community prevalence; to ascertain antibiotic use in low resource communities,
487 including perceptions and health seeking behaviours, and to assess the burden of
488 disease attributable to antibiotic resistance in LMICs (80).

489

490 **Mitigating strategies based on evidence from One Health studies**

491 The paucity of One Health intervention studies in LMICs makes it difficult to identify
492 successful mitigation strategies. However, multisectoral interventions at national
493 scales will increase with the implementation of NAPs. Strategies for containment of
494 ABR in animal health are likely to focus on reducing antimicrobial use. The VIParc
495 study plans to target small-scale poultry farms and provide farmers with a locally-
496 adapted veterinary support service to help them reduce their reliance on
497 antimicrobials (83). Other studies have advocated for the withdrawal of non-
498 therapeutic use of agricultural antimicrobials in countries such as India and Vietnam

499 where antibiotic use in animal feeds is high (37,84). Many countries have existing
500 policies to restrict the addition of antibiotics to livestock feed but policy enforcement
501 remains a challenge. Biosecurity in farming systems and improved waste
502 management, along with water, sanitation and hygiene in human and animal
503 systems, are important strategies for the prevention of ABR transmission (85–87).

504

505 **Discussion**

506 Data are sparse on the distribution and concentrations of ABR bacteria and antibiotic
507 resistance genes in humans, animals and the environment at a meaningful spatial
508 and temporal scale in low resource settings. The scarcity of integrated
509 epidemiological data prevents a true assessment of prevalence of ABR and
510 transmission pathways, let alone assessment of transmission risk. Where detailed
511 studies have been conducted, the evidence points to shared microbiomes and
512 resistomes in humans, animals and the environment following gradients of exposure
513 or contamination (75). Future studies require sufficient statistical power and
514 representative samples from interconnected livestock and humans, rather than
515 convenience sampling of populations with no direct associations. Similarly,
516 environmental assessments require an ecosystem-wide approach to mapping genes
517 and bacteria (88). As well as microbiological and epidemiological research, studies
518 need to document “informal food economies, changing household-level and
519 community-level food preparation and storage techniques, and the structural
520 impediments many people face accessing safe and regulated foods.” (79).
521 Molecular approaches such as whole genome sequencing (WGS) of bacteria and
522 metagenomic analysis of whole DNA, coupled with analytical tools in bioinformatics,
523 will increasingly replace conventional culture-dependent systems. Application of
524 metagenomics allows the assessment of clonal diversity and similarity among human
525 and animal bacterial isolates, providing greater insight into the shared resistance
526 genes – but will not necessarily identify the source. While this technology is being
527 rapidly adopted in many countries, some will lag behind because of a lack of
528 technical skills, expertise and laboratory facilities (16). Even with increasing
529 affordability of WGS the costs are likely to be prohibitive for many programmes in
530 low resource settings.

531

532 The studies included in this critical appraisal do not represent a systematic review
533 and, as such, may not be comprehensive. With the vast range of disciplines involved
534 in research relating to ABR, it is challenging to collate studies from all fields. A wider
535 adoption of One Health approaches in future will bring together disparate disciplines
536 and data sources and provide much greater insights.

537

538 A One Health paradigm is particularly relevant in LMICs because of the risk of
539 community-acquired ABR infections; the high prevalence of infectious diseases (89);
540 the high rates of colonisation with resistant commensal bacteria (20); the close
541 interactions between humans, animals and the outdoor environment and the high
542 levels of environmental contamination with antibiotic residues; heavy metals and
543 other co-selecting compounds (63).

544

545 The term 'eco-epidemiological' has been used to describe the complexity of the
546 overlapping ecologies of ABR in humans, animals and the environment (39).
547 Quantitative microbiological and epidemiological studies are needed to understand
548 risk, dose-response effects and strategies for intervention. In-depth qualitative
549 studies are required to elucidate the drivers of antibiotic use, waste management,
550 and economic pressures, as well as the facilitators and barriers to change. In LMICs,
551 where income generation is critical, economic drivers may be particularly powerful.
552 This needs to be considered when developing mitigation strategies or interventions.
553 Finally, systems-based modelling is needed to understand the key pathways of ABR
554 transmission. As proposed by Wernli and colleagues (90), ABR research needs to
555 focus on outcomes (epidemiology), processes (drivers and practices) as well as
556 structures (regulations and current control policies). Single discipline studies will fail
557 to identify the most effective methods to contain antibiotic resistance.
558 Multidisciplinary and holistic studies employing One Health approaches are required
559 in low resource settings.

560

561 **References**

- 562 1. King LJ et al. Executive summary of the AVMA One Health Initiative Task
563 Force report, *J Am Vet Med Assoc.* 2008;233:259–261.
564 doi:10.2460/javma.233.2.259.
- 565 2. Robinson TP, Bu DP, Carrique-Mas J, Fèvre EM, Gilbert M, Grace D, et al.

- 566 Antibiotic resistance is the quintessential One Health issue. *Trans R Soc Trop*
567 *Med Hyg.* 2016;377–80. doi:10.1093/trstmh/trw048
- 568 3. Jinks T, Lee N, Sharland M, Rex J, Gertler N, Diver M, et al. A time for action:
569 Antimicrobial resistance needs global response. *Bull World Health Organ.*
570 2016;94:558–558A. doi:10.1093/trstmh/trw048
- 571 4. World Health Organization. Global Priority List of Antibiotic Resistant Bacteria
572 to Guide Research, Discovery, and Development of New Antibiotics. Geneva;
573 WHO. 2017. Pp1-7. doi.org/10.1016/S1473-3099(09)70222-1
- 574 5. Mshana SE, Matee M, Rweyemamu M. Antimicrobial resistance in human and
575 animal pathogens in Zambia, Democratic Republic of Congo, Mozambique and
576 Tanzania: an urgent need of a sustainable surveillance system. *Ann Clin*
577 *Microbiol Antimicrob.* 2013;12:28. doi:10.1186/1476-0711-12-28
- 578 6. Kumar GS, Adithan C, Harish BN, Sujatha S, Roy G, Malini A. Antimicrobial
579 resistance in India: A review. *J Nat Sci Biol Med.* 2013;4:286–91.
580 doi:10.4103/0976-9668.116970
- 581 7. Gandra S, Joshi J, Trett A, & Sankhil Lamkang A. (2017). Scoping Report on
582 Antimicrobial Resistance in India. Washington, DC: Center for Disease
583 Dynamics, Economics & Policy. Retrieved from [https://www.cddep.org/wp-](https://www.cddep.org/wp-content/uploads/2017/11/AMR-India-scoping-report.pdf)
584 [content/uploads/2017/11/AMR-India-scoping-report.pdf](https://www.cddep.org/wp-content/uploads/2017/11/AMR-India-scoping-report.pdf)
- 585 8. Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug resistance
586 among clinically relevant bacterial isolates in sub-Saharan Africa: A systematic
587 review. *J Antimicrob Chemother.* 2014;69:2337–53. doi: 10.1093/jac/dku176
- 588 9. Huynh BT, Padget M, Garin B, Delarocque-Astagneau E, Guillemot D.
589 Bacterial neonatal sepsis and antibiotic resistance in low-income countries.
590 *Lancet* 2016;6:387:533–4. doi:10.1186/s12879-015-0843-x
- 591 10. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al.
592 Antimicrobial resistance in developing countries. Part I: recent trends and
593 current status. *Lancet Infect Dis.* 2005;5:481–93. doi:10.1016/S1473-
594 3099(05)70189-4
- 595 11. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N,
596 et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis.*
597 2013;13:1057–98. doi:10.1016/S1473-3099(13)70318-9
- 598 12. World Health Organization. Antimicrobial resistance: global report on
599 surveillance. Geneva: WHO; 2014. doi:1.4.2014

- 600 13. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R,
601 et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan,
602 and the UK: a molecular, biological, and epidemiological study. *Lancet Infect*
603 *Dis.* 2010;10:597–602. doi:10.1016/S1473-3099(10)70143-2
- 604 14. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global,
605 regional, and national causes of child mortality: An updated systematic
606 analysis for 2010 with time trends since 2000. *Lancet*; 2012;379(9832):2151–
607 61. doi:10.1016/S0140-6736(12)60560-1
- 608 15. Van Den Bogaard AE, Stobberingh EE. Epidemiology of resistance to
609 antibiotics: Links between animals and humans. *Int J Antimicrob Agents.*
610 2000;14:327–35. doi:10.1016/S0924-8579(00)00145-X
- 611 16. WHO. Integrated Surveillance of Antimicrobial Resistance in Foodborne
612 Bacteria: Application of a One Health Approach. Geneva: WHO. 2017. Pp87.
613 http://apps.who.int/iris/bitstream/10665/91778/1/9789241506311_eng.pdf
- 614 17. Hasan B, Drobni P, Drobni M, Alam M, Olsen B. Dissemination of NDM-1.
615 *Lancet Infect Dis.* 2012;12:99-100-2. doi:10.1016/S1473-3099(11)70333-4
- 616 18. Woerther P-L, Angebault C, Jacquier H, Hugede H-C, Janssens A-C, Sayadi S,
617 et al. Massive increase, spread, and exchange of extended spectrum β -
618 lactamase-encoding genes among intestinal enterobacteriaceae in
619 hospitalized children with severe acute malnutrition in Niger. *Clin Infect Dis.*
620 2011;53:677–85. doi:10.1093/cid/cir522
- 621 19. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases
622 in Asia. *Clin Microbiol Infect.* 2008;14(suppl):159–65. doi:10.1111/j.1469-
623 0691.2007.01855.x
- 624 20. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal
625 colonization with extended-spectrum beta-lactamase-producing
626 Enterobacteriaceae and risk factors among healthy individuals: a systematic
627 review and metaanalysis. *Clin Infect Dis.* 2016;63:310–8.
628 doi:10.1093/cid/ciw283
- 629 21. Miao Z, Li S, Wang L, Song W, Zhou Y. Antimicrobial resistance and molecular
630 epidemiology of ESBL-producing *Escherichia coli* isolated from outpatients in
631 town hospitals of Shandong Province, China. *Front Microbiol.* 2017;8:1–8.
632 doi:10.3389/fmicb.2017.00063
- 633 22. Zhang J, Zheng B, Zhao L, Wei Z, Ji J, Li L, et al. Nationwide high prevalence

- 634 of CTX-M and an increase of CTX-M-55 in *Escherichia coli* isolated from
635 patients with community-onset infections in Chinese county hospitals. BMC
636 Infect Dis. 2014;14:1–10. doi:10.1186/s12879-014-0659-0
- 637 23. Rutgersson C, Fick J, Marathe N, Kristiansson E, Janzon A, Angelin M, et al.
638 Fluoroquinolones and qnr genes in sediment, water, soil, and human fecal
639 flora in an environment polluted by manufacturing discharges. Environ Sci
640 Technol. 2014;48:7825–32. doi:10.1021/es501452a
- 641 24. Amaya E, Reyes D, Vilchez S, Paniagua M, Möllby R, Nord CE, et al.
642 Antibiotic resistance patterns of intestinal *Escherichia coli* isolates from
643 Nicaraguan children. J Med Microbiol. 2011;60:216–22.
644 doi:10.1099/jmm.0.020842-0
- 645 25. Randrianirina F, Ratsima EH, Ramparany L, Randremanana R, Rakotonirina
646 HC, Andriamanantena T, et al. Antimicrobial resistance of bacterial
647 enteropathogens isolated from stools in Madagascar. BMC Infect Dis 2014;
648 14:104. doi:10.1186/1471-2334-14-104
- 649 26. Monira S, Shabnam SA, Ali SI, Sadique A, Johura FT, Rahman KZ, et al.
650 Multi-drug resistant pathogenic bacteria in the gut of young children in
651 Bangladesh. Gut Pathog 2017;9:19. doi:10.1186/s13099-017-0170-4
- 652 27. Shin H-H, Cho S-H. Prevalence of antimicrobial resistance in *Escherichia coli*
653 strains isolated from fishery workers. Osong Public Heal Res Perspect;
654 2013;4:72–5. doi:10.1016/j.phrp.2013.03.001
- 655 28. Herindrainy P, Randrianirina F, Ratovoson R, Hariniana E, Buisson Y, Genel N,
656 et al. Rectal carriage of extended-spectrum beta-lactamase-producing Gram-
657 negative bacilli in community settings in Madagascar. PLoS One 2011;6.
658 doi:10.1371/journal.pone.0022738
- 659 29. Arcilla MS, van Hattem JM, Haverkate MR, Bootsma MCJ, van Genderen PJJ,
660 Goorhuis A, et al. Import and spread of extended-spectrum β -lactamase-
661 producing Enterobacteriaceae by international travellers (COMBAT study): a
662 prospective, multicentre cohort study. Lancet Infect Dis; 2017;17:78–85.
663 doi:10.1016/S1473-3099(16)30319-X
- 664 30. Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin S a, Robinson TP, et
665 al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A.
666 2015;(16):1–6. doi:10.1073/pnas.1503141112
- 667 31. Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: Drivers and

- 668 opportunities for action. PLoS Med. 2016;13:e1001974.
669 doi:10.1371/journal.pmed.1001974
- 670 32. Krishnasamy V, Otte J, Silbergeld E. Antimicrobial use in Chinese swine and
671 broiler poultry production. Antimicrob Resist Infect Control 2015;4:17.
672 doi:10.1186/s13756-015-0050-y
- 673 33. Shanta IS, Hasnat MA, Zeidner N, Gurley ES, Azziz-Baumgartner E, Sharker
674 MAY, et al. Raising backyard poultry in rural Bangladesh: financial and
675 nutritional benefits, but persistent risky practices. Transbound Emerg Dis.
676 2016;64:1454-1464. doi:10.1111/tbed.12536
- 677 34. van den Bogaard AE, London N, Driessen C, Stobberingh EE. Antibiotic
678 resistance of faecal *Escherichia coli* in poultry, poultry farmers and poultry
679 slaughterers. J Antimicrob Chemother. 2001;47:763–71.
680 doi:10.1093/jac/47.6.763
- 681 35. Graham JP, Eisenberg JNS, Trueba G, Zhang L, Johnson TJ. Small-scale
682 food animal production and antimicrobial resistance: mountain, molehill, or
683 something in-between? Environ Health Perspect. 2017;125:1–5.
684 doi:10.1289/EHP2116
- 685 36. Nguyen VT, Carrique-Mas JJ, Ngo TH, Ho HM, Ha TT, Campbell JI, et al.
686 Prevalence and risk factors for carriage of antimicrobial-resistant *Escherichia*
687 *coli* on household and small-scale chicken farms in the Mekong Delta of
688 Vietnam. J Antimicrob Chemother. 2015;70:2144–52. doi:10.1093/jac/dkv053
- 689 37. Brower CH, Mandal S, Hayer S, Sran M, Zehra A, Patel SJ, et al. The
690 prevalence of extended-spectrum beta-lactamase-producing multidrug-
691 resistant *Escherichia coli* in poultry chickens and variation according to farming
692 practices in Punjab, India. Environ Health Perspect. 2017;125:1–10.
693 doi:10.1289/EHP292
- 694 38. Andoh LA, Dalsgaard A, Obiri-Danso K, Newman MJ, Barco L, Olsen JE.
695 Prevalence and antimicrobial resistance of *Salmonella* serovars isolated from
696 poultry in Ghana. Epidemiol Infect. 2016;144:3288–99.
697 doi:10.1017/S0950268816001126
- 698 39. Braykov NP, Eisenberg JNS, Grossman M, Zhang L, Vasco K, Cevallos W, et
699 al. Antibiotic resistance in animal and environmental samples associated with
700 small-scale poultry farming in northwestern Ecuador. Msphere 2016
701 10;1:e00021-15. doi:10.1128/mSphere.00021-15

- 702 40. Gondam Kamini M, Tatfo Keutchatang F, Yangoua Mafo H, Kansci G, Medoua
703 Nama G. Antimicrobial usage in the chicken farming in Yaoundé, Cameroon: a
704 cross-sectional study. *Int J Food Contam*. 2016;3:10. doi:10.1186/s40550-016-
705 0034-6
- 706 41. Om C, McLaws ML. Antibiotics: Practice and opinions of Cambodian
707 commercial farmers, animal feed retailers and veterinarians. *Antimicrob Resist*
708 *Infect Control*. 2016;5:1–8. doi:10.1186/s13756-016-0147-y
- 709 42. Li P, Wu D, Liu K, Suolang S, He T, Liu X, et al. Investigation of antimicrobial
710 resistance in *Escherichia coli* and Enterococci isolated from Tibetan pigs.
711 *PLoS One*. 2014;9(4). doi:10.1371/journal.pone.0095623
- 712 43. Samanta I, Joardar SN, Das PK, Das P, Sar TK, Dutta TK, et al. Virulence
713 repertoire, characterization, and antibiotic resistance pattern analysis of
714 *Escherichia coli* isolated from backyard layers and their environment in India.
715 *Avian Dis* 2014;58:39–45. doi:10.1637/10586-052913-Reg.1
- 716 44. Hussain A, Shaik S, Ranjan A, Nandanwar N, Tiwari SK, Majid M, et al. Risk of
717 transmission of antimicrobial resistant *Escherichia coli* from commercial broiler
718 and free-range retail chicken in India. *Front Microbiol*. 2017;8.
719 doi:10.3389/fmicb.2017.02120
- 720 45. Roess AA, Winch PJ, Akhter A, Afroz D, Ali NA, Shah R, et al. Household
721 animal and human medicine use and animal husbandry practices in rural
722 Bangladesh: Risk factors for emerging zoonotic disease and antibiotic
723 resistance. *Zoonoses Public Health*. 2015;62:569–78. doi:10.1111/zph.12186
- 724 46. Taylor NGH, Verner-Jeffreys DW, Baker-Austin C. Aquatic systems:
725 Maintaining, mixing and mobilising antimicrobial resistance? *Trends Ecol Evol*.
726 2011;26:278–84. doi:10.1016/j.tree.2011.03.004
- 727 47. Pham DK, Chu J, Do NT, Brose F, Degand G, Delahaut P, et al. Monitoring
728 antibiotic use and residue in freshwater aquaculture for domestic use in
729 Vietnam. *Ecohealth*. 2015;12:480–9. doi:10.1007/s10393-014-1006-z
- 730 48. Jiang H-X, Tang D, Liu Y-H, Zhang X-H, Zeng Z-L, Xu L, et al. Prevalence and
731 characteristics of beta-lactamase and plasmid-mediated quinolone resistance
732 genes in *Escherichia coli* isolated from farmed fish in China. *J Antimicrob*
733 *Chemother*. 2012;67:2350–3. doi:10.1093/jac/dks250
- 734 49. Zheng H, Zeng Z, Chen S, Liu Y, Yao Q, Deng Y, et al. Prevalence and
735 characterisation of CTX-M β -lactamases amongst *Escherichia coli* isolates

- 736 from healthy food animals in China. *Int J Antimicrob Agents* 2012;39:305–10.
737 doi:10.1016/j.ijantimicag.2011.12.001
- 738 50. Ma J, Liu JH, Lv L, Zong Z, Sun Y, Zheng H, et al. Characterization of
739 extended-spectrum β -lactamase genes found among *Escherichia coli* isolates
740 from duck and environmental samples obtained on a duck farm. *Appl Environ*
741 *Microbiol.* 2012;78:3668–73. doi:10.1128/AEM.07507-11
- 742 51. Abdissa R, Haile W, Fite AT, Beyi AF, Agga GE, Edao BM, et al. Prevalence of
743 *Escherichia coli* O157:H7 in beef cattle at slaughter and beef carcasses at
744 retail shops in Ethiopia. *BMC Infect Dis.* 2017;17:277. doi:10.1186/s12879-
745 017-2372-2
- 746 52. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of
747 plasmid-mediated colistin resistance mechanism MCR-1 in animals and
748 human beings in China: a microbiological and molecular biological study.
749 *Lancet Infect Dis.* 2016;16:161–8. doi:10.1016/S1473-3099(15)00424-7
- 750 53. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative
751 organisms. *Int J Antimicrob Agents* 2017;49:526-535.
752 doi:10.1016/j.ijantimicag.2016.11.029
- 753 54. Zhu YG, Johnson TA, Su JQ, Qiao M, Guo GX, Stedtfeld RD. Diverse and
754 abundant antibiotic resistance genes in Chinese swine farms. *Proc Natl Acad*
755 *Sci U S A.* 2013;110. doi:10.1073/pnas.1222743110
- 756 55. Nhung N, Cuong N, Thwaites G, Carrique-Mas J. Antimicrobial usage and
757 antimicrobial resistance in animal production in southeast Asia: A review.
758 *Antibiotics.* 2016;5:37. doi:10.3390/antibiotics5040037
- 759 56. Gao L, Hu J, Zhang X, Wei L, Li S, Miao Z, et al. Application of swine manure
760 on agricultural fields contributes to extended- spectrum β -lactamase producing
761 *Escherichia coli* spread in Tai'an, China. *Front Microbiol.* 2015;6.
762 doi:10.3389/fmicb.2015.00313
- 763 57. Donkor ES, Newman MJ, Yeboah-Manu D. Epidemiological aspects of non-
764 human antibiotic usage and resistance: Implications for the control of antibiotic
765 resistance in Ghana. *Trop Med Int Heal.* 2012;17:462–8. doi:10.1111/j.1365-
766 3156.2012.02955.x
- 767 58. Addis Z, Kebede N, Worku Z, Gezahegn H, Yirsaw A, Kassa T. Prevalence
768 and antimicrobial resistance of *Salmonella* isolated from lactating cows and in
769 contact humans in dairy farms of Addis Ababa: A cross sectional study. *BMC*

- 770 Infect Dis. 2011;11:222. doi:10.1186/1471-2334-11-222
- 771 59. Woolhouse M, Ward M, Van Bunnik B, Farrar J. Antimicrobial resistance in
772 humans, livestock and the wider environment. *Philos Trans R Soc B*;
773 2015;370(1670). doi:10.1098/rstb.2014.0083
- 774 60. Pruden A, Larsson JDG, Amézquita A, Collignon P, Brandt KK, Graham DW,
775 et al. Management options for reducing the release of antibiotics and antibiotic
776 resistance genes to the environment. *Environ Health Perspect.* 2013;121:878–
777 85. doi:10.1289/ehp.1206446
- 778 61. Diwan V, Chandran SP, Tamhankar AJ, Stalsby Lundborg C, Macaden R.
779 Identification of extended-spectrum beta-lactamase and quinolone resistance
780 genes in *Escherichia coli* isolated from hospital wastewater from central India.
781 *J Antimicrob Chemother.* 2012;67:857–9. doi:10.1093/jac/dkr564
- 782 62. Chandran SP, Diwan V, Tamhankar AJ, Joseph B V., Rosales-Klintz S,
783 Mundayoor S, et al. Detection of carbapenem resistance genes and
784 cephalosporin, and quinolone resistance genes along with *oqxAB* gene in
785 *Escherichia coli* in hospital wastewater: A matter of concern. *J Appl Microbiol.*
786 2014;117:984-995 doi:10.1111/jam.12591
- 787 63. Lübbert C, Baars C, Dayakar A, Lippmann N, Rodloff AC, Kinzig M, et al.
788 Environmental pollution with antimicrobial agents from bulk drug manufacturing
789 industries in Hyderabad, South India, is associated with dissemination of
790 extended-spectrum beta-lactamase and carbapenemase-producing pathogens.
791 *Infection* 2017;45:479-491. doi:10.1007/s15010-017-1007-2
- 792 64. Islam MA, Islam M, Hasan R, Hossain MI, Nabi A, Rahman M, et al.
793 Environmental spread of NDM-1-producing multi-drug resistant bacteria in
794 Dhaka, Bangladesh. *Appl Environ Microbiol.* 2017;AEM.00793-17.
795 doi:10.1128/AEM.00793-17
- 796 65. Amaya E, Reyes D, Paniagua M, Calderón S, Rashid MU, Colque P, et al.
797 Antibiotic resistance patterns of *Escherichia coli* isolates from different aquatic
798 environmental sources in León, Nicaragua. *Clin Microbiol Infect.*
799 2012;18:E347-54. doi:10.1111/j.1469-0691.2012.03930.x
- 800 66. Graham DW, Olivares-Rieumont S, Knapp CW, Lima L, Werner D, Bowen E.
801 Antibiotic resistance gene abundances associated with waste discharges to
802 the Almendares river near Havana, Cuba. *Environ Sci Technol.* 2011;45:418–
803 24. doi:10.1021/es102473z

- 804 67. Talukdar PK, Rahman M, Rahman M, Nabi A, Islam Z, Hoque MM, et al.
805 Antimicrobial Resistance, Virulence factors and genetic diversity of *Escherichia*
806 *coli* isolates from household water supply in Dhaka, Bangladesh. PLoS One.
807 2013;8(4). doi:10.1371/journal.pone.0061090
- 808 68. Hassan MM, Ahmed SA, Rahman KA, Biswas TK. Pattern of medical waste
809 management: existing scenario in Dhaka City, Bangladesh. BMC Public Health.
810 2008;8:36. doi:10.1186/1471-2458-8-36
- 811 69. Patwary MA, O'Hare WT, Sarker MH. An illicit economy: Scavenging and
812 recycling of medical waste. J Environ Manage. 2011;92:2900-2906.
813 doi:10.1016/j.jenvman.2011.06.051
- 814 70. Chethana T, Thapsey H, Gautham MS, Sreekantaiah P, Suryanarayana SP.
815 Situation analysis and issues in management of biomedical waste in select
816 small health care facilities in a ward under Bruhat Bengaluru Mahanagara
817 Palike, Bangalore, India. J Community Health. 2014;39:310–5.
818 doi:10.1007/s10900-013-9761-2
- 819 71. Ahammad ZS, Sreekrishnan TR, Hands CL, Knapp CW, Graham DW.
820 Increased waterborne bla NDM-1 resistance gene abundances associated with
821 seasonal human pilgrimages to the Upper Ganges River. Environ Sci Technol.
822 2014;48:3014–20. doi:10.1021/es405348h
- 823 72. Diwan V, Tamhankar AJ, Khandal RK, Sen S, Aggarwal M, Marothi Y, et al.
824 Antibiotics and antibiotic-resistant bacteria in waters associated with a hospital
825 in Ujjain, India. BMC Public Health. 2010;10:414. doi:10.1186/1471-2458-10-
826 414
- 827 73. Dhaka P, Vijay D, Vergis J, Negi M, Kumar M, Mohan V, et al. Genetic
828 diversity and antibiogram profile of diarrhoeagenic *Escherichia coli* pathotypes
829 isolated from human, animal, foods and associated environmental sources.
830 Infect Ecol Epidemiol 2016;18:31055. doi:10.3402/iee.v6.31055
- 831 74. Dulo F, Feleke A, Szonyi B, Fries R, Baumann MPO, Grace D. Isolation of
832 multidrug-resistant *Escherichia coli* O157 from goats in the somali region of
833 Ethiopia: A cross-sectional, abattoir-based study. PLoS One. 2015;10:
834 doi:10.1371/journal.pone.0142905
- 835 75. Pehrsson EC, Tsukayama P, Patel S, Mejía-Bautista M, Sosa-Soto G,
836 Navarrete KM, et al. Interconnected microbiomes and resistomes in low-
837 income human habitats. Nature. 2016;533:212–6. doi:10.1038/nature17672

- 838 76. Stålsby Lundborg C, Diwan V, Pathak A, Purohit MR, Shah H, Sharma M, et al.
839 Protocol: a “One health” two year follow-up, mixed methods study on antibiotic
840 resistance, focusing children under 5 and their environment in rural India. BMC
841 Public Health. 2015;15:1321. doi:10.1186/s12889-015-2632-2
- 842 77. UNICEF and ICDDR,B. Evaluation of avian influenza communication for
843 development initiative- Improving biosecurity in live bird markets. 2015. Dhaka:
844 icddr,b. Pp160.
- 845 78. Finley RL, Collignon P, Larsson DGJ, Mcewen SA, Li XZ, Gaze WH, et al. The
846 scourge of antibiotic resistance: The important role of the environment. Clin
847 Infect Dis. 2013;57:704–10. doi:10.1093/cid/cit355
- 848 79. Carruth L, Roess AA, Terefe Y, Hosh FM, Salman MD. Antimicrobial
849 resistance and food safety in Africa. Lancet Infect Dis. 2017;17:575–6.
850 doi:10.1016/S1473-3099(17)30273-6
- 851 80. Grundmann H, Klugman KP, Walsh T, Ramon-Pardo P, Sigauque B, Khan W,
852 et al. A framework for global surveillance of antibiotic resistance. Drug Resist
853 Updat 2011;14:79–87. doi:10.1016/j.drug.2011.02.007
- 854 81. Donado-Godoy P, Castellanos R, León M, Arevalo A, Clavijo V, Bernal J, et al.
855 The establishment of the colombian integrated program for antimicrobial
856 resistance surveillance (COIPARS): A pilot project on poultry farms,
857 slaughterhouses and retail market. Zoonoses Public Health. 2015;62(s1):58–
858 69. doi:10.1111/zph.12192
- 859 82. Zaidi MB, McDermott PF, Campos FD, Chim R, Leon M, Vazquez G, et al.
860 Antimicrobial-resistant *Campylobacter* in the food chain in Mexico. Foodborne
861 Pathog Dis. 2012;9:841–7. doi:10.1089/fpd.2012.1127
- 862 83. Carrique-Mas JJ, Rushton J. Integrated interventions to tackle antimicrobial
863 usage in animal production systems: The ViParc project in Vietnam. Front
864 Microbiol. 2017 13;8:1062. doi:10.3389/fmicb.2017.01062
- 865 84. Van Cuong N, Nhung NT, Nghia NH, Mai Hoa NT, Trung NV, Thwaites G, et al.
866 Antimicrobial consumption in medicated feeds in Vietnamese pig and poultry
867 production. Ecohealth 2016;13:490–8. doi:10.1007/s10393-016-1130-z
- 868 85. Wuijts S, van den Berg HHJL, Miller J, Abebe L, Sobsey M, Andremont A, et al.
869 Towards a research agenda for water, sanitation and antimicrobial resistance.
870 J Water Health 2017;15:175–84. doi:10.2166/wh.2017.124
- 871 86. O’Neill J. Tackling drug-resistant infections globally: final report and

- 872 recommendations. the Review on Antimicrobial Resistance. London. 2016.
873 Available at: [https://amr-](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf)
874 [review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf)
- 875 87. Founou LL, Founou RC, Essack SY. Antibiotic resistance in the food chain: A
876 developing country-perspective. *Front Microbiol* 2016 23;7:1–19.
877 doi:10.3389/fmicb.2016.01881
- 878 88. Huijbers PMC, Blaak H, De Jong MCM, Graat EAM, Vandenbroucke-Grauls
879 CMJE, De Roda Husman AM. Role of the Environment in the Transmission of
880 Antimicrobial Resistance to Humans: A Review. *Environ Sci Technol*.
881 2015;49:11993–2004. doi:10.1021/acs.est.5b02566
- 882 89. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M, Laxminarayan
883 R, et al. Achieving global targets for antimicrobial resistance. *Science*.
884 2016;353:1057–875. doi:10.1126/science.aaf9286
- 885 90. Wernli D, Jørgensen PS, Harbarth S, Carroll SP, Laxminarayan R, Levrat N, et
886 al. Antimicrobial resistance: The complex challenge of measurement to inform
887 policy and the public. *PLoS Med*. 2017;14:1–9.
888 doi:10.1371/journal.pmed.1002378

889

890 **Acknowledgements**

891 The authors gratefully acknowledge funding support from the UK Antimicrobial
892 Resistance Cross Council Initiative (NERC/BBSRC/MRC) grant number
893 NE/N019555/1 with additional support from the EPSRC Bridging the Gaps in AMR
894 award EP/M027341/1.

895 **Ethics statement:** No ethical clearances were required for the purposes of the
896 review.

897

898 **Competing interests statement:** The authors declare no competing interests

899

900 **Data accessibility statement:** No original data have been used to produce this
901 manuscript. All information in the review can be accessed from published articles.

902

903 **Authors' contributions statement:** All authors contributed to the intellectual
904 conception for the paper, the search, retrieval and synthesis of information presented
905 and the writing and editing of the manuscript. All authors approved the final version.